纳米技术在乳腺癌化疗中的应用研究进展

doi:10.3969/j.issn.1004-616x.2015.01.017

摘要/Abstract

摘要：

乳腺癌已成为全世界女性最高发的癌症，严重威胁女性健康。化疗作为癌症治疗的主要手段之一，延长了患者的生存期，降低了死亡率。传统的化疗药物一方面因非特异性杀伤正常细胞而给人体来了严重损伤，另一方面因肿块局部化疗药物未达到有效治疗剂量，导致了肿瘤细胞产生耐药。纳米颗粒独特的物理、化学及生物学特性使其能安全有效地运输化疗药物至肿瘤位点，显著降低了化疗药物的毒副作用，提高了化疗效果，开创了“乳腺癌靶向治疗”的新时代。本文就纳米技术在乳腺癌化疗中的作用机制及其应用进行综述，旨在为研发高效、安全、多功能的新型纳米制剂提供参考。

关键词: 乳腺肿瘤, 化疗, 纳米技术, 药物载体

刘丽桃，谢妮，郭文鹏. 纳米技术在乳腺癌化疗中的应用研究进展[J]. 癌变·畸变·突变, doi: 10.3969/j.issn.1004-616x.2015.01.017.

参考文献

[1] Jemal A，Bray F，Center MM，et al. Global cancer statistics[J]. CA Cancer J Clin，2011，61(2)：69-90.

[2] Yang Y，Wang H. Perspectives of nanotechnology in minimally invasive therapy of breast cancer[J]. J Healthc Eng，2013，4(1)：67-86.

[3] Tanaka T，Decuzzi P，Cristofanilli M，et al. Nanotechnology for breast cancer therapy[J]. Biomed Microdevices，2009，11(1)：49-63.

[4] Barenholz Y. Doxil(R)-the first FDA-approved nano-drug：lessons learned[J]. J Control Release，2012，160(2)：117-134.

[5] 贾晋斌，韦青燕. 阿霉素脂质体的研究进展[J]. 中国肿瘤， 2011， 20(5)：372-377.

[6] Brigger I，Dubernet C，Couvreur P. Nanoparticles in cancer therapy and diagnosis[J]. Adv Drug Deliv Rev，2002，54(5)：631-651.

[7] Oerlemans C，Bult W，Bos M，et al. Polymeric micelles in anticancer therapy：targeting，imaging and triggered release[J]. Pharm Res， 2010，27(12)：2569-2589.

[8] Senthil KP，Pastoriza-Santos I，Rodriguez-Gonzalez B，et al. High-yield synthesis and optical response of gold nanostars[J]. Nanotechnology， 2008，19(1)：15606.

[9] Heath JR，Davis ME. Nanotechnology and cancer[J]. Annu Rev Med，2008，59(9)：251-265.

[10] 梅梅，袁守军. 实体瘤的EPR效应及治疗策略[J]. 解放军药学学报，2008(4)：345-346.

[11] Marcucci F，Lefoulon F. Active targeting with particulate drug carriers in tumor therapy：fundamentals and recent progress[J]. Drug Discov Today，2004，9(5)：219-228.

[12] Gref R，Minamitake Y，Peracchia MT，et al. Biodegradable long-circulating polymeric nanospheres[J]. Science，1994，263(5153)： 1600-1603.

[13] Paliwal SR，Paliwal R，Agrawal GP，et al. Liposomal nanomedicine for breast cancer therapy[J]. Nanomedicine (Lond)，2011，6(6)：1085-1100.

[14] Liu Y，Solomon M，Achilefu S. Perspectives and potential applications of nanomedicine in breast and prostate cancer[J]. Med Res Rev，2013， 33(1)：3-32.

[15] Slamon DJ，Godolphin W，Jones LA，et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer[J]. Science， 1989，244(4905)：707-712.

[16] Huang W，Zhang J，Dorn HC，et al. Assembly of bio-nanoparticles for double controlled drug release[J]. PLoS One，2013，8(9)：e74679.

[17] Grobmyer SR，Morse DL，Fletcher B，et al. The promise of nanotechnology for solving clinical problems in breast cancer[J]. J Surg Oncol，2011，103(4)：317-325.

[18] Zhu L，Ma J，Jia N，et al. Chitosan-coated magnetic nanoparticles as carriers of 5-fluorouracil：preparation，characterization and cytotoxicity studies[J]. Colloids Surf B Biointerfaces，2009，68(1)：1-6.

[19] 王玉，王东凯，孙念. pH-敏感型纳米制剂概述[J]. 中国药剂学杂志网络版，2009，7(2)：72-76.

[20] Sanna V，Pala N，Sechi M. Targeted therapy using nanotechnology： focus on cancer[J]. Int J Nanomedicine，2014，9：467-483.

[21] Ghaffar KA，Giddam AK，Zaman M，et al. Liposomes as nanovaccine delivery systems[J]. Curr Top Med Chem，2014，14(9)：1194-1208.

[22] Gregoriadis G，Wills EJ，Swain CP，et al. Drug-carrier potential of liposomes in cancer chemotherapy[J]. Lancet，1974，1(7870)：1313-1316.

[23] Wetzler M，Thomas DA，Wang ES，et al. Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia[J]. Clin Lymphoma Myeloma Leuk，2013，13(4)：430-434.

[24] Chang HI，Yeh MK. Clinical development of liposome-based drugs：formulation，characterization，and therapeutic efficacy[J]. Int J Nanomedicine，2012，7(1)：49-60.

[25] Brown S，Khan DR. The treatment of breast cancer using liposome technology[J]. J Drug Deliv，2012，2012：212965.

[26] Gabizon A，Shmeeda H，Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin：review of animal and human studies[J]. Clin Pharmacokinet，2003，42(5)：419-436.

[27] Laginha KM，Verwoert S，Charrois GJ，et al. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors[J]. Clin Cancer Res，2005，11(19 Sup 1)：6944-6949.

[28] Yatvin MB，Weinstein JN，Dennis WH，et al. Design of liposomes for enhanced local release of drugs by hyperthermia[J]. Science，1978， 202(4374)：1290-1293.

[29] Kheirolomoom A，Lai CY，Tam SM，et al. Complete regression of local cancer using temperature-sensitive liposomes combined with ultrasound-mediated hyperthermia[J]. J Control Release，2013， 172 (1)：266-273.

[30] Kullberg M，Owens JL，Mann K. Listeriolysin O enhances cytoplasmic delivery by Her-2 targeting liposomes[J]. J Drug Target，2010，18(4)： 313-320.

[31] Huang W，Zhang J，Dorn HC，et al. Assembly of bio-nanoparticles for double controlled drug release[J]. PLoS One，2013，8(9)：e74679.

[32] Schnitzer JE，Oh P. Antibodies to SPARC inhibit albumin binding to SPARC，gp60，and microvascular endothelium[J]. Am J Physiol， 1992，263(6 Pt 2)：1872-1879.

[33] Blanco E，Ferrari M. Emerging nanotherapeutic strategies in breast cancer[J]. Breast，2014，23(1)：10-18.

[34] Bakkialakshmi S，Chandrakala D. A spectroscopic investigations of anticancer drugs binding to bovine serum albumin[J]. Spectrochim Acta A Mol Biomol Spectrosc，2012，88(1)：2-9.

[35] Taheri A，Dinarvand R，Ahadi F，et al. The in vivo antitumor activity of LHRH targeted methotrexate-human serum albumin nanoparticles in 4T1 tumor-bearing Balb/c mice[J]. Int J Pharm，2012，431(1/2)：183-189.

[36] Yamamoto Y，Kawano I，Iwase H. Nab-paclitaxel for the treatment of breast cancer：efficacy，safety，and approval[J]. Onco Targets Ther， 2011，4：123-136.

[37] Gradishar WJ，Tjulandin S，Davidson N，et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer[J]. J Clin Oncol，2005，23(31)：7794-7803.

[38] Guan ZZ，Li QL，Feng F，et al. Superior efficacy of a Cremophor-free albumin-bound paclitaxel compared with solvent-based paclitaxel in Chinese patients with metastatic breast cancer[J]. Asia Pac J Clin Onco，2009，5(3)：165-174.

[39] Chirgwin J，Chua SL. Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens：a clinical review[J]. Breast，2011，20(5)：394-406.

[40] Abbasi S，Paul A，Shao W，et al. Cationic albumin nanoparticles for enhanced drug delivery to treat breast cancer：preparation and in vitro assessment[J]. J Drug Deliv，2012，2012：686108.

[41] 王生，陆茵，钱文慧，等. 细胞电荷：抗肿瘤研究潜在的重要靶标[J]. 中国药理学通报，2010，26(12)：1541-1544.

[42] Jithan A，Madhavi K，Madhavi M，et al. Preparation and characterization of albumin nanoparticles encapsulating curcumin intended for the treatment of breast cancer[J]. Int J Pharm Investig， 2011，1(2)：119-125.

[43] Gradishar WJ，Krasnojon D，Cheporov S，et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer[J]. J Clin Oncol， 2009，27(22)：3611-3619.

[44] 黄果，蒋序林. 热敏性可降解高分子胶束药物载体的研究进展[J]. 高分子通报，2014，(2)：60-67.

[45] Lee KS，Chung HC，Im SA，et al. Multicenter phase II trial of Genexol-PM，a Cremophor-free，polymeric micelle formulation of paclitaxel，in patients with metastatic breast cancer[J]. Breast Cancer Res Treat，2008，108(2)：241-250.

[46] Burris Iii H，Infante J，Spigel D，et al. A phase I dose-escalation study of NK012[J]. J Clin Oncol，2008，26(15)：25-38.

[47] Hamaguchi T，Doi T，Eguchi-Nakajima T，et al. Phase I study of NK012，a novel SN-38-incorpora ting micellar nanoparticle，in adult patients with solid tumors[J]. Clin Cancer Res，2010，16(20)：5058-5066.

[48] Matsumura Y. Preclinical and clinical studies of NK012，an SN-38-incorporating polymeric micelles，which is designed based on EPR effect[J]. Adv Drug Deliver Rev，2011，63(3)：184-192.

[49] Kutty RV，Feng SS. Cetuximab conjugated vitamin E TPGS micelles for targeted delivery of docetaxel for treatment of triple negative breast cancers[J]. Biomaterials，2013，34(38)：10160-10171.

[50] Gao ZG，Tian L，Hu J，et al. Prevention of metastasis in a 4T1 murine breast cancer model by doxorubicin carried by folate conjugated pH sensitive polymeric micelles[J]. J Control Release，2011，152(1)：84-89.

[51] Abdel-Rahman MA，Al-Abd AM. Thermoresponsive dendrimers based on oligoethylene glycols：design，synthesis and cytotoxic activity against MCF-7 breast cancer cells[J]. Eur J Med Chem，2013， 69(1)：848-854.

[52] Ueda K，Asai Y，Yoshimura Y，et al. Effect of oil-in-water lipid emulsions prepared with fish oil or soybean oil on the growth of MCF-7 cells and HepG2 cells[J]. J Pharm Pharmacol，2008，60(8)：1069-1075.

[53] Mendes S，Graziani SR，Vitorio TS，et al. Uptake by breast carcinoma of a lipidic nanoemulsion after intralesional injection into the patients：a new strategy for neoadjuvant chemotherapy[J]. Gynecol Oncol，2009， 112(2)：400-404.

[54] Galanzha EI，Kim JW，Zharov VP. Nanotechnology-based molecular photoacoustic and photothermal flow cytometry platform for in-vivo detection and killing of circulating cancer stem cells[J]. J Biophotonics， 2009，2(12)：725-735.

[55] Varshosaz J，Sadeghi-Aliabadi H，Ghasemi S，et al. Use of magnetic folate-dextran-retinoic acid micelles for dual targeting of doxorubicin in breast cancer[J]. Biomed Res Int，2013，2013：680712.

[56] 袁丽，王蓓娣，唐倩倩，等. 介孔二氧化硅纳米粒子应用于可控药物传输系统的若干新进展[J]. 有机化学，2010，30(5)：640-647.

[57] Blanco E，Sangai T，Hsiao A，et al. Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment[J]. Cancer Lett，2013，334(2)：245-252.